Kite Pharma Investors Seek Appraisal After $11B Gilead Buy
Shareholders of biopharmaceutical company Kite Pharma Inc. filed an appraisal petition Monday in Delaware demanding a court valuation of their holdings in the company following its $11.9 billion acquisition by Gilead...To view the full article, register now.
Already a subscriber? Click here to view full article